Page 783 - Read Online

Yoneoka et al. Hepatoma Res 2020;6:67 I http://dx.doi.org/10.20517/2394-5079.2020.57 Page 11 of 11

5. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium
90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010;116:1305-14.
6. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
7. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, et al; Liver Transplantation French Study Group. Liver transplantation
for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology
2012;143:986-94.e3; quiz e14-5.
8. Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular
carcinoma. Liver Transpl 2013;19:634-45.
9. Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a
systematic review. Hepatol Int 2008;2:17-30.
10. Li J, Han X, Yu X, Xu Z, Yang G, et al. Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular
carcinoma: circulating tumor cells and circulating tumor DNA. J Exp Clin Cancer Res 2018;37:213.
11. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid
tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124.
12. Qi X, Li J, Deng H, Li H, Su C, et al. Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: a
systematic review and meta-analysis of observational studies. Oncotarget 2016;7:45283-301.
13. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, et al. Prognostic role of platelet to lymphocyte ratio in solid
tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014;23:1204-12.
14. Li C, Wen TF, Yan LN, Li B, Wang WT, et al. Postoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the
outcomes of hepatocellular carcinoma. J Surg Res 2015;198:73-9.
15. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
16. Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interaction in solid tumors. Int J Cancer 2012;130:2747-60.
17. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, mechanisms, and consequences. Immunity 2019;51:27-41.
18. Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after
liver transplantation via inflammatory microenvironment. J Hepatol 2013;58:58-64.
19. Pinato DJ, Sharma R. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in
hepatocellular carcinoma. Transl Res 2012;160:146-52.
20. Tian XC, Liu XL, Zeng FR, Chen Z, Wu DH. Platelet-to-lymphocyte ratio acts as an independent risk factor for patients with hepatitis B
virus-related hepatocellular carcinoma who received transarterial chemoembolization. Eur Rev Med Pharmacol Sci 2016;20:2302-9.
21. Taussig MD, Irene Koran ME, Mouli SK, Ahmad A, Geevarghese S, et al. Neutrophil to lymphocyte ratio predicts disease progression
following intra-arterial therapy of hepatocellular carcinoma. HPB (Oxford) 2017;19:458-64.
22. Soydal C, Araz M, Nak D, Akkus P, Baltacioğlu MH, et al. Analysis of prognostic factors in patients receiving transarterial
radioembolization for unresectable hepatocellular carcinoma. Nucl Med Commun 2020;41:73-7.
23. Sukato DC, Tohme S, Chalhoub D, Han K, Zajko A, et al. The prognostic role of neutrophil-to-lymphocyte ratio in patients with
unresectable hepatocellular carcinoma treated with radioembolization. J Vasc Interv Radiol 2015;26:816-24.e1.
24. D’Emic N, Engelman A, Molitoris J, Hanlon A, Sharma NK, et al. Prognostic significance of neutrophil-lymphocyte ratio and platelet-
lymphocyte ratio in patients treated with selective internal radiation therapy. J Gastrointest Oncol 2016;7:269-77.
25. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, et al. Assessment of liver function in patients with hepatocellular
carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015;33:550-8.
26. Gui B, Weiner AA, Nosher J, Lu SE, Foltz GM, et al. Assessment of the albumin-bilirubin (ALBI) grade as a prognostic indicator for
hepatocellular carcinoma patients treated with radioembolization. Am J Clin Oncol 2018;41:861-6.
27. Mohammadi H, Abuodeh Y, Jin W, Frakes J, Friedman M, et al. Using the albumin-bilirubin (ALBI) grade as a prognostic marker for
radioembolization of hepatocellular carcinoma. J Gastrointest Oncol 2018;9:840-6.
28. Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer 2016;16:431-46.
29. Yan M, Jurasz P. The role of platelets in the tumor microenvironment: from solid tumors to leukemia. Biochim Biophys Acta
2016;1863:392-400.
30. Ménétrier-Caux C, Ray-Coquard I, Blay JY, Caux C. Lymphopenia in cancer patients and its effects on response to immunotherapy: an
opportunity for combination with cytokines? J Immunother Cancer 2019;7:85.